Ubitus Partners with Maizuru City, Kyoto to Launch AI Data Center Project, Advancing the Deployment of a Top-Tier AI GPU Center in Japan
29.1.2026 07:00:00 CET | Business Wire | Press Release
Ubitus K.K. (Headquarters: Shinjuku, Tokyo; Representative Director & CEO: Wesley Kuo), a global leader in cloud streaming and AI solutions, today announced that it will hold a land signing ceremony and press conference with Maizuru City, Kyoto Prefecture, on January 29, 2026.
At the event, Ubitus will officially unveil its comprehensive plan to construct an AI Data Center in Maizuru City, marking the company’s transition into the physical construction phase of its initiative to build a top-tier AI GPU center in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128944842/en/
Ubitus will launch its Maizuru City AI Data Center project on January 29, marking the first step toward building a top-tier AI GPU center in Japan. Powered by NVIDIA Blackwell GPUs and NeoCloud, the project strengthens Japan’s AI infrastructure and regional development.
This land agreement represents the first major milestone following Ubitus’ selection for a large-scale investment grant from Japan’s Ministry of Economy, Trade and Industry (METI), under which the company committed to building Japan’s leading AI GPU infrastructure. It also symbolizes a significant step forward in collaboration between the central government, local governments, and the private sector to advance AI infrastructure development in Japan.
Maizuru City AI Data Center: The First Step Toward a Top-Tier AI GPU Center in Japan
The planned AI Data Center will be located in Maizuru City, Kyoto Prefecture, on a site spanning approximately 2.3 hectares (around 23,000 square meters). The site offers favorable land conditions and infrastructure readiness, with proximity to port and logistics facilities, making it well suited for the development of high-density, high-reliability AI computing infrastructure.
In terms of development approach, the Maizuru City AI Data Center will adopt a phased construction strategy.
Phase 1 will focus on building the data center and progressively deploying core facilities and operational capabilities. Phase 2 will expand capacity in response to the evolving demands of generative AI and large language models, supporting medium- to long-term growth in compute requirements.
This flexible expansion plan ensures that the AI Data Center can scale steadily in line with industry demand while maintaining operational efficiency and long-term sustainability.
Based on current plans, construction is expected to begin in 2026, with major development targeted for completion within 2027.
Next-Generation AI Compute Core Powered by NVIDIA Blackwell × NeoCloud
The Maizuru City AI Data Center will fully adopt NVIDIA’s latest-generation Blackwell GPU architecture, specifically designed to support high-efficiency training and inference for generative AI and large language models. The platform supports high-density GPU deployment and sustained large-scale workloads, positioning the facility among the few in Japan capable of meeting next-generation AI compute demands.
The overall computing architecture will be centered on NeoCloud, which features hierarchical scheduling, distributed computing, and flexible resource management. This design enables dynamic allocation of GPU resources based on regional, industry-specific, and project-level AI needs—enhancing compute efficiency while reducing latency and avoiding the bottlenecks associated with centralized architectures.
Through the deep integration of NVIDIA Blackwell GPUs and the NeoCloud architecture, the Maizuru City AI Data Center will deliver high scalability and system resilience, serving as a critical compute foundation for the long-term development of Japan’s AI industry.
Why Maizuru City: A Strategic City for the AI Era
Ubitus selected Maizuru City as a key location for its AI Data Center based on the city’s multiple strengths essential for AI infrastructure development, including:
- Stable power supply conditions
- A site location selected with disaster risk considerations in mind
- Well-developed port and logistics infrastructure
- A highly coordinated collaboration environment between government and the private sector
Together, these factors make Maizuru City an ideal location that balances stability, scalability, and long-term operational requirements. They also provide critical support for Ubitus’ broader vision of building cross-regional GPU infrastructure across Japan.
Long-Term AI Collaboration with the Japanese Government: From Model Development to Infrastructure Deployment
The Maizuru City AI Data Center project builds upon Ubitus’ long-term AI strategy in Japan, spanning from model development to the deployment of compute infrastructure.
2024 | Selected for METI’s “GENIAC” Program: Development of a 405B East Asia Large Language Model
Under the GENIAC program, Ubitus developed a 405-billion-parameter (405B) large language model optimized for East Asian languages, supporting Japanese, Traditional Chinese, and English. The model has been applied across cultural, tourism, and educational domains, demonstrating strong multilingual comprehension performance in multiple benchmark evaluations.
2025 | Launch of a Leading Tourism and Cultural AI Language Model in Japan
Building on the 405B model, Ubitus introduced an AI solution integrating Japanese cultural and local knowledge. In Maizuru City, the AI virtual guide “Chokimaru” was deployed to provide real-time multilingual Q&A, guided tours, and translation services in Japanese, English, and Chinese—bringing AI applications into real-world tourism settings.
2026 | Advancement of Cross-Regional GPU Infrastructure (NeoCloud)
With NeoCloud at its core, Ubitus is constructing a GPU computing environment capable of dynamically scaling to meet regional demands, gradually forming a highly resilient and efficient nationwide AI compute network.
Looking Ahead
Looking forward, Ubitus will continue to deepen its technological and industrial collaboration in Japan with NeoCloud at the center of its strategy. Through the construction and operation of AI infrastructure, the company aims to create local employment opportunities in technical and operational roles, foster talent development, and support regional industrial upgrading.
At the same time, Ubitus will build scalable and flexible AI computing infrastructure, strengthen localized deployment capabilities, and lower barriers for industries and local governments across Japan to adopt AI. This will accelerate real-world AI applications in tourism, culture, education, healthcare, and enterprise sectors.
Through its dual-track strategy of “AI model development × compute infrastructure deployment,” Ubitus will continue to inject long-term, scalable innovation momentum into Japan’s and East Asia’s AI ecosystem.
About Ubitus
As a member of the NVIDIA Connect program, Ubitus leverages NVIDIA’s support and cutting-edge GPU technology to accelerate AI innovation. The company delivers advanced AI solutions, including UbiGPT (a large language model), UbiONE (an AI-powered avatar creation platform), and UbiArt (an image generation tool), providing customized solutions to meet the diverse needs of various industries.
As a cloud gaming pioneer, Ubitus enables Nintendo and other game companies to establish cloud gaming services and supports the global streaming of multimedia content, including interactive and virtual reality experiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128944842/en/
Contacts
TEL : +81-3-6435-3295 (Tokyo)
+886-2-2717-6123 (Taipei)
Media contact: pr@ubitus.net
Business inquiry: contact@ubitus.net
Website:www.ubitus.net -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ubitus.net%
2F&esheet=54405041&newsitemid=20260128944842&lan=en-US&anchor=www.ubitus.net&ind
ex=1&md5=c1e68b7898206d35e04f0260acf7e23d
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom